Immunosuppressants

Marian Fireman, Andrea F. DiMartini, Scott C. Armstrong, Kelly L. Cozza

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Immunosuppressants are prescribed to prevent rejection of transplanted tissues and organs and are also used in the treatment of autoimmune disorders. Consultation-liaison psychiatrists increasingly encounter patients taking these agents as the number of transplant recipients increases and the indications for the use of immunosuppressants expands. These drugs have potentially deleterious physical, mental, and biochemical side effects. In addition, transplant recipients and patients with autoimmune disorders commonly have comorbid illnesses that require pharmacologic treatment. The management of these patients is challenging secondary to the severity of these illnesses, the number of medications prescribed, and the potential for adverse drug-drug interactions. Knowledge of the pharmacokinetic properties of these drugs and the potential for serious drug-drug interactions that cause alterations in serum levels of the immunosuppressant medications is essential. Increased serum levels may cause serious toxic effects and decreased serum levels may lead to rejection of the transplanted organ or worsening of the autoimmune disorder. Adverse events may also occur when serum levels of medications prescribed for comorbid illnesses are altered by administration of immunosuppressants. The pharmacokinetic drug-drug interaction profiles of the glucocorticoids, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, azathioprine, and monoclonal antibodies are discussed in this review.

Original languageEnglish (US)
Pages (from-to)354-360
Number of pages7
JournalPsychosomatics
Volume45
Issue number4
DOIs
StatePublished - Jul 2004

Fingerprint

Immunosuppressive Agents
Drug Interactions
Pharmaceutical Preparations
Serum
Pharmacokinetics
Mycophenolic Acid
Poisons
Azathioprine
Tacrolimus
Proxy
Sirolimus
Cyclosporine
Glucocorticoids
Psychiatry
Referral and Consultation
Monoclonal Antibodies
Drugs
Therapeutics
Rejection (Psychology)
Transplant Recipients

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)

Cite this

Fireman, M., DiMartini, A. F., Armstrong, S. C., & Cozza, K. L. (2004). Immunosuppressants. Psychosomatics, 45(4), 354-360. https://doi.org/10.1176/appi.psy.45.4.354

Immunosuppressants. / Fireman, Marian; DiMartini, Andrea F.; Armstrong, Scott C.; Cozza, Kelly L.

In: Psychosomatics, Vol. 45, No. 4, 07.2004, p. 354-360.

Research output: Contribution to journalArticle

Fireman, M, DiMartini, AF, Armstrong, SC & Cozza, KL 2004, 'Immunosuppressants', Psychosomatics, vol. 45, no. 4, pp. 354-360. https://doi.org/10.1176/appi.psy.45.4.354
Fireman M, DiMartini AF, Armstrong SC, Cozza KL. Immunosuppressants. Psychosomatics. 2004 Jul;45(4):354-360. https://doi.org/10.1176/appi.psy.45.4.354
Fireman, Marian ; DiMartini, Andrea F. ; Armstrong, Scott C. ; Cozza, Kelly L. / Immunosuppressants. In: Psychosomatics. 2004 ; Vol. 45, No. 4. pp. 354-360.
@article{ce5260706287446f8bc3c9c9ba61c795,
title = "Immunosuppressants",
abstract = "Immunosuppressants are prescribed to prevent rejection of transplanted tissues and organs and are also used in the treatment of autoimmune disorders. Consultation-liaison psychiatrists increasingly encounter patients taking these agents as the number of transplant recipients increases and the indications for the use of immunosuppressants expands. These drugs have potentially deleterious physical, mental, and biochemical side effects. In addition, transplant recipients and patients with autoimmune disorders commonly have comorbid illnesses that require pharmacologic treatment. The management of these patients is challenging secondary to the severity of these illnesses, the number of medications prescribed, and the potential for adverse drug-drug interactions. Knowledge of the pharmacokinetic properties of these drugs and the potential for serious drug-drug interactions that cause alterations in serum levels of the immunosuppressant medications is essential. Increased serum levels may cause serious toxic effects and decreased serum levels may lead to rejection of the transplanted organ or worsening of the autoimmune disorder. Adverse events may also occur when serum levels of medications prescribed for comorbid illnesses are altered by administration of immunosuppressants. The pharmacokinetic drug-drug interaction profiles of the glucocorticoids, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, azathioprine, and monoclonal antibodies are discussed in this review.",
author = "Marian Fireman and DiMartini, {Andrea F.} and Armstrong, {Scott C.} and Cozza, {Kelly L.}",
year = "2004",
month = "7",
doi = "10.1176/appi.psy.45.4.354",
language = "English (US)",
volume = "45",
pages = "354--360",
journal = "Psychosomatics",
issn = "0033-3182",
publisher = "American Psychiatric Publishing Inc.",
number = "4",

}

TY - JOUR

T1 - Immunosuppressants

AU - Fireman, Marian

AU - DiMartini, Andrea F.

AU - Armstrong, Scott C.

AU - Cozza, Kelly L.

PY - 2004/7

Y1 - 2004/7

N2 - Immunosuppressants are prescribed to prevent rejection of transplanted tissues and organs and are also used in the treatment of autoimmune disorders. Consultation-liaison psychiatrists increasingly encounter patients taking these agents as the number of transplant recipients increases and the indications for the use of immunosuppressants expands. These drugs have potentially deleterious physical, mental, and biochemical side effects. In addition, transplant recipients and patients with autoimmune disorders commonly have comorbid illnesses that require pharmacologic treatment. The management of these patients is challenging secondary to the severity of these illnesses, the number of medications prescribed, and the potential for adverse drug-drug interactions. Knowledge of the pharmacokinetic properties of these drugs and the potential for serious drug-drug interactions that cause alterations in serum levels of the immunosuppressant medications is essential. Increased serum levels may cause serious toxic effects and decreased serum levels may lead to rejection of the transplanted organ or worsening of the autoimmune disorder. Adverse events may also occur when serum levels of medications prescribed for comorbid illnesses are altered by administration of immunosuppressants. The pharmacokinetic drug-drug interaction profiles of the glucocorticoids, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, azathioprine, and monoclonal antibodies are discussed in this review.

AB - Immunosuppressants are prescribed to prevent rejection of transplanted tissues and organs and are also used in the treatment of autoimmune disorders. Consultation-liaison psychiatrists increasingly encounter patients taking these agents as the number of transplant recipients increases and the indications for the use of immunosuppressants expands. These drugs have potentially deleterious physical, mental, and biochemical side effects. In addition, transplant recipients and patients with autoimmune disorders commonly have comorbid illnesses that require pharmacologic treatment. The management of these patients is challenging secondary to the severity of these illnesses, the number of medications prescribed, and the potential for adverse drug-drug interactions. Knowledge of the pharmacokinetic properties of these drugs and the potential for serious drug-drug interactions that cause alterations in serum levels of the immunosuppressant medications is essential. Increased serum levels may cause serious toxic effects and decreased serum levels may lead to rejection of the transplanted organ or worsening of the autoimmune disorder. Adverse events may also occur when serum levels of medications prescribed for comorbid illnesses are altered by administration of immunosuppressants. The pharmacokinetic drug-drug interaction profiles of the glucocorticoids, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, azathioprine, and monoclonal antibodies are discussed in this review.

UR - http://www.scopus.com/inward/record.url?scp=3042555335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042555335&partnerID=8YFLogxK

U2 - 10.1176/appi.psy.45.4.354

DO - 10.1176/appi.psy.45.4.354

M3 - Article

C2 - 15232051

AN - SCOPUS:3042555335

VL - 45

SP - 354

EP - 360

JO - Psychosomatics

JF - Psychosomatics

SN - 0033-3182

IS - 4

ER -